Ann: Race Initiates FTO Melanoma Preclinical Study, page-50

Exactly right. This announcement explains that the melanoma project is signed and underway. We have an outstanding team working on this project and I am very confident we are going to produce a whole lot of very valuable IP that will enable us to move into Phase II trials in early 2022 for Melanoma. While the focus is on overcoming checkpoint inhibitor resistance, the project will be covering a lot more than this. A lot of work has gone into designing an amazing research program and we will see the fruits of this work over the coming months - we well be releasing updates to the market as the results come to hand as we did with the breast cancer program.

This announcement was released today because we signed the contract today. Under the ASX continuous disclosure rules we can’t sit on price sensitive information and release on a different day just because it would be more convenient for us. When the contract was signed we had to announce. I should add that this is just one small part of a whole lot of announcements that will be made before the end of the quarter as projects and programs are finalised.

Why Melanoma was chosen is covered in the 2020 AGM video so I encourage everyone who doesn’t understand why melanoma to watch it again.

The breast cancer project announcement last year was also marked price sensitive. Why is this news price sensitive? It is price sensitive because it is telling everyone that Pillar 1 underway and not just a plan. I would hope most people would recognise the significance of this news.